肉瘤新药他泽司他详细介绍！

Epithelioid sarcoma is a very rare and extremely aggressive soft tissue sarcoma. The survival period is often only a few months. Tazerestat was developed to treat epithelioid sarcoma. After 20 years, it was finally approved for marketing in the United States in 2020. Today we will learn more about the new sarcoma drug!

In fact, tazerestat is the first and only approved EZH2 inhibitor and the first treatment specifically for epithelioid sarcoma. It is approved for marketing in the United States for the treatment of adults and pediatric patients 16 years and older with metastatic/locally advanced epithelioid sarcoma (ES) who are not suitable for complete resection. The drug is easy to take. The recommended dose is 800 mg, taken orally twice a day. It can be taken with or without food.

In terms of treatment effect, a phase 2 trial showed that after treatment with tazerestat in 62 patients with advanced metastatic or locally advanced epithelioid sarcoma, the overall objective response rate (ORR) was 15%. Even if the tumor did not shrink significantly, 67% of the patients did not continue to worsen, and the response lasted for more than half a year or even longer. While 1.6% of patients achieved complete response, the partial response rate was 13%. The safety profile is also relatively tolerable. Common side effects of tazerestat are musculoskeletal pain, nausea, decreased appetite, upper respiratory tract infection, fatigue, vomiting, constipation, pain, abdominal pain, etc.

Tazerestat is a methyltransferase inhibitor that inhibits the proliferation of B-cell lymphoma cell lines in vitro, has a greater inhibitory effect on the proliferation of lymphoma cell lines with mutated EZH2, and has shown anti-tumor activity in mouse xenograft models of B-cell lymphoma with or without EZH2 gain-of-function mutations.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: